SSEA3-positive c-kit-negative Cardiac Progenitor Cell Isolation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for isolating cardiac stem cells rely heavily on c-kit expression, which may not be sufficient for myocardial repair, as they do not fully account for the diverse phenotypes within myocardial tissue, and existing isolation techniques may introduce pathogens or be inefficient.
Innovation Solution
Isolation and expansion of SSEA3-positive/c-kit-negative cardiac progenitor cells (EA-CPCs) from post-natal myocardium, which are CD34-negative and CD45-negative, using methods that include enzymatic dissociation, culture, and purification techniques like FACS and MACS to enrich for these cells, allowing for the preparation of pharmaceutical compositions capable of repairing damaged myocardium.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If c-kit positive cardiac stem cells are isolated using antigen-antibody interactions and magnetic bead sorting, then the isolation method is clinically safe (limits pathogen introduction), but the isolation efficiency and purity are insufficient to account for diverse phenotypes within myocardial tissue
Solution Approach 1:
The patent segments the cardiac stem cell population into distinct subpopulations based on c-kit expression levels (c-kit low, c-kit negative, c-kit positive). This segmentation allows for the isolation of previously overlooked c-kit negative EA-CPCs that constitute a significant portion of the cardiac progenitor cell population but were not captured by traditional c-kit positive selection methods.
Solution Approach 2:
The patent introduces flow cytometry as an intermediary technique to bridge the gap between magnetic bead sorting and the need for phenotype diversity. Flow cytometry enables multi-parameter analysis including c-kit, SSEA-3, CD34, and CD45 markers simultaneously, allowing for the identification and isolation of c-kit negative EA-CPCs that would be missed by magnetic bead sorting alone.
2Ease of operation
If traditional c-kit based isolation methods are used, then the method is well-established and easy to perform, but it fails to isolate the full diversity of cardiac progenitor cell phenotypes present in myocardial tissue
Solution Approach 1:
The patent employs flow cytometry with multiple antibody conjugates that can simultaneously detect c-kit, SSEA-3, CD34, and CD45 markers. This multi-functional approach allows a single isolation procedure to capture diverse cardiac progenitor cell phenotypes including c-kit negative EA-CPCs, c-kit positive CSCs, and other intermediate populations that constitute the full spectrum of cardiac progenitors.
Solution Approach 2:
The patent changes the detection parameters from single-marker c-kit positivity to multi-marker analysis including c-kit expression levels, SSEA-3 positivity, and negativity for CD34 and CD45. This parameter expansion enables the identification of c-kit negative EA-CPCs and other phenotypes that were invisible under traditional single-parameter selection criteria.
3Manufacturing precision
If c-kit positive cardiac stem cells are targeted for myocardial repair, then the therapy focuses on a specific cell population, but it may not fully address the need for diverse cell types in tissue regeneration
Solution Approach 1:
The patent applies the principle of local quality by providing different cell populations with different functional properties. c-kit negative EA-CPCs can differentiate into cardiomyocytes, smooth muscle cells, and endothelial cells, while c-kit positive CSCs have different differentiation potentials. This local quality differentiation within the cell therapy product allows for more comprehensive tissue regeneration compared to using a single cell population.
Solution Approach 2:
The patent creates a composite cell therapy product that can include multiple cardiac progenitor cell populations (c-kit negative EA-CPCs, c-kit positive CSCs, and intermediate populations) in defined ratios. This composite approach combines the regenerative advantages of different cell types, potentially achieving superior myocardial repair outcomes compared to monotherapy with a single cell population.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The isolated EA-CPCs can differentiate into mature cardiomyocytes and endothelium, effectively regenerating and repairing damaged myocardium, improving myocardial function and structure, and can be administered as a pharmaceutical composition to treat various heart conditions.
Implementation Method 1
disrupting a cardiac tissue sample isolated from a post-natal subject to obtain tissue fragments and/or single cells
Implementation Method 2
purification techniques like FACS and MACS to enrich for these cells
Implementation Method 3
purification techniques like FACS and MACS to enrich for these cells
Data Source
AI summary
Provided are pharmaceutical compositions that include a pharmaceutically acceptable carrier and isolated post-natal cardiac progenitor cells (CPCs) and/or progeny cells thereof that are SSEA3-positive and c-kit-negative. Also provided are methods for preparing cells capable of repairing damaged myocardium, methods for isolating populations of SSEA3-positive/c-kit-negative CPCs from cardiac tissue samples, methods for preparing an isolated cell population enriched in post-natal SSEA3-positive/c-kit-negative CPCs, therapeutic methods for using the presently disclosed cells and populations of cells to treat subjects in need thereof, and cell cultures that contain the presently disclosed cells and populations of cells.